Document is current
Any future updates will be listed below
-
Authors
Atkinson, Thomas M.
Lynch, Kathleen A.
Vera, Jacqueline
Olivares, Nuria Mendoza
Webb, Andrew
Diamond, Lisa C.
González, Javier
Lubetkin, Erica I.
Bucher, Gary
Rosa-Cunha, Isabella
Berry-Lawhorn, J. Michael
Levine, Rebecca
Aboulafia, David
Schouten, Jeffrey
Holland, Susan M.
Cella, David
Palefsky, Joel M.
-
Funding
Funding for this research was provided by:
National Institutes of Health (2 UM1 CA121947-09, 3U54CA137788-08S1, P30 CA008748)
- License Information
-
More Information
Article History
Received: 11 July 2022
Accepted: 21 September 2022
First Online: 11 October 2022
Declarations
:
: This study was reviewed and deemed exempt by the US NCI’s Cancer Therapy Evaluation Program and the institutional review boards at each participating study site.
: Not applicable.
: RL has received grant funding from Medtronic. JMP serves as a Consultant with Antiva Biosciences, Vir Biotechnology, and Virion Therapeutics. JMP serves as a Scientific Advisory Board Speaker with Merck. All other authors have no disclosures.
